UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Response of vegetation and birds to severe wind disturbance and salvage logging in a southern boreal forest

Forest ecology and management, 2008-08, Vol.256 (5), p.863-871

2008

Volltextzugriff (PDF)

Thirty Years of Post-fire Succession in a Southern Boreal Forest Bird Community

The American midland naturalist, 2008-04, Vol.159 (2), p.421-433

2008

Volltextzugriff (PDF)

BIRD COMMUNITIES AFTER BLOWDOWN IN A LATE-SUCCESSIONAL GREAT LAKES SPRUCE-FIR FOREST

The Wilson journal of ornithology, 2005-12, Vol.117 (4), p.341

2005

Volltextzugriff (PDF)

BIRD COMMUNITIES AFTER BLOWDOWN IN A LATE-SUCCESSIONAL GREAT LAKES SPRUCE-FIR FOREST

The Wilson bulletin (Wilson Ornithological Society), 2005-12, Vol.117 (4), p.341-352

2005

Volltextzugriff (PDF)

Half-Life of Serum Elimination of Perfluorooctanesulfonate, Perfluorohexanesulfonate, and Perfluorooctanoate in Retired Fluorochemical Production Workers

Environmental health perspectives, 2007-09, Vol.115 (9), p.1298-1305

2007

Volltextzugriff (PDF)

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

Journal of clinical oncology, 1997-06, Vol.15 (6), p.2403-2413

1997

Volltextzugriff (PDF)

Umbralisib, a novel PI3Kδ and casein kinase-1ε inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation, first-in-human study

The lancet oncology, 2018-04, Vol.19 (4), p.486-496

2018

Volltextzugriff (PDF)

Paclitaxel, bevacizumab, and everolimus/placebo as first-line treatment for patients with metastatic HER2-negative breast cancer: a randomized placebo-controlled phase II trial of the Sarah Cannon Research Institute

Breast cancer research and treatment, 2015-11, Vol.154 (1), p.89-97

2015

Volltextzugriff (PDF)

Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral Mammalian Target of Rapamycin Inhibitor Everolimus in Patients With Advanced Solid Tumors

Journal of clinical oncology, 2008-04, Vol.26 (10), p.1588-1595

2008

Volltextzugriff (PDF)

Broad Anti-tumor Activity of a Small Molecule that Selectively Targets the Warburg Effect and Lipogenesis

Cancer cell, 2015-07, Vol.28 (1), p.42-56

2015

Volltextzugriff (PDF)

Perfluorooctanesulfonate and Other Fluorochemicals in the Serum of American Red Cross Adult Blood Donors

Environmental health perspectives, 2003-12, Vol.111 (16), p.1892-1901

2003

Volltextzugriff (PDF)

International Union of Basic and Clinical Pharmacology. XC. multisite pharmacology: recommendations for the nomenclature of receptor allosterism and allosteric ligands

Pharmacological reviews, 2014-10, Vol.66 (4), p.918-947

2014

Volltextzugriff (PDF)

Development and pharmacological evaluation of a new chemical series of potent pan-ERR agonists, identification of SLU-PP-915

European journal of medicinal chemistry, 2023-10, Vol.258, p.115582-115582, Article 115582

2023

Volltextzugriff (PDF)

Randomized, Double-Blind, Placebo-Controlled, Phase II Trial of Sorafenib and Erlotinib or Erlotinib Alone in Previously Treated Advanced Non–Small-Cell Lung Cancer

Journal of clinical oncology, 2011-06, Vol.29 (18), p.2582-2589

2011

Volltextzugriff (PDF)

TMEM16A/ANO1 Channels Contribute to the Myogenic Response in Cerebral Arteries

Circulation research, 2012-09, Vol.111 (8), p.1027-1036

2012

Volltextzugriff (PDF)

Improvements in Survival and Clinical Benefit With Gemcitabine as First-Line Therapy for Patients With Advanced Pancreas Cancer: A Randomized Trial

Journal of clinical oncology, 2023-12, Vol.41 (36), p.5482-5492

2023

Volltextzugriff (PDF)

Safety and Activity of Varlilumab, a Novel and First-in-Class Agonist Anti-CD27 Antibody, in Patients With Advanced Solid Tumors

Journal of clinical oncology, 2017-06, Vol.35 (18), p.2028-2036

2017

Volltextzugriff (PDF)

A Randomized, Double‐Blinded, Phase II Trial of Carboplatin and Pemetrexed with or without Apatorsen (OGX‐427) in Patients with Previously Untreated Stage IV Non‐Squamous‐Non‐Small‐Cell Lung Cancer: The SPRUCE Trial

The oncologist (Dayton, Ohio), 2019-12, Vol.24 (12), p.e1409-e1416

2019

Volltextzugriff (PDF)

Phase I/II study of bevacizumab with BKM120, an oral PI3K inhibitor, in patients with refractory solid tumors (phase I) and relapsed/refractory glioblastoma (phase II)

Journal of neuro-oncology, 2019-09, Vol.144 (2), p.303-311

2019

Volltextzugriff (PDF)

LXR-mediated inhibition of CD4+ T helper cells

PloS one, 2012-09, Vol.7 (9), p.e46615-e46615

2012

Volltextzugriff (PDF)

Synthetic ERRα/β/γ Agonist Induces an ERRα-Dependent Acute Aerobic Exercise Response and Enhances Exercise Capacity

ACS chemical biology, 2023-04, Vol.18 (4), p.756-771

2023

Volltextzugriff (PDF)

Forebrain-selective AMPA-receptor antagonism guided by TARP γ-8 as an antiepileptic mechanism

Nature medicine, 2016-12, Vol.22 (12), p.1496-1501

2016

Volltextzugriff (PDF)

Origin of a novel regulatory module by duplication and degeneration of an ancient plant transcription factor

Molecular phylogenetics and evolution, 2014-12, Vol.81, p.159-173

2014

Volltextzugriff (PDF)

Erlotinib plus either pazopanib or placebo in patients with previously treated advanced non–small cell lung cancer: A randomized, placebo‐controlled phase 2 trial with correlated serum proteomic signatures

Cancer, 2018-06, Vol.124 (11), p.2355-2364

2018

Volltextzugriff (PDF)

Randomized phase 2 trial of pemetrexed, pemetrexed/bevacizumab, and pemetrexed/carboplatin/bevacizumab in patients with stage IIIB/IV non–small cell lung cancer and an Eastern Cooperative Oncology Group performance status of 2

Cancer, 2018-05, Vol.124 (9), p.1982-1991

2018

Volltextzugriff (PDF)

1 – 25 von 215

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(202)
Mit Volltextzugriff
(176)

Publikationsform

Artikel
(209)
Tagungsberichte
(6)

Sprache

Englisch
(215)
Japanisch
(2)

Erscheinungsjahr

n.n

Thema

Science & Technology
(148)
Life Sciences & Biomedicine
(130)
Humans
(113)
Female
(77)
Male
(72)
Middle Aged
(63)
Adult
(61)
Aged
(61)
Oncology
(61)
Biological And Medical Sciences
(54)
Medical Sciences
(49)
Aged, 80 And Over
(35)
Treatment Outcome
(27)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(26)
Animals
(23)
Pharmacology. Drug Treatments
(22)
Antineoplastic Agents
(21)
Chemotherapy
(21)
Antineoplastic Combined Chemotherapy Protocols - Adverse Effects
(20)
Pharmacology & Pharmacy
(19)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Response of vegetation and birds to severe wind disturbance and salvage logging in a southern boreal forest

Thirty Years of Post-fire Succession in a Southern Boreal Forest Bird Community

BIRD COMMUNITIES AFTER BLOWDOWN IN A LATE-SUCCESSIONAL GREAT LAKES SPRUCE-FIR FOREST

BIRD COMMUNITIES AFTER BLOWDOWN IN A LATE-SUCCESSIONAL GREAT LAKES SPRUCE-FIR FOREST

Half-Life of Serum Elimination of Perfluorooctanesulfonate, Perfluorohexanesulfonate, and Perfluorooctanoate in Retired Fluorochemical Production Workers

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

Umbralisib, a novel PI3Kδ and casein kinase-1ε inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation, first-in-human study

Paclitaxel, bevacizumab, and everolimus/placebo as first-line treatment for patients with metastatic HER2-negative breast cancer: a randomized placebo-controlled phase II trial of the Sarah Cannon Research Institute

Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral Mammalian Target of Rapamycin Inhibitor Everolimus in Patients With Advanced Solid Tumors

Broad Anti-tumor Activity of a Small Molecule that Selectively Targets the Warburg Effect and Lipogenesis

Perfluorooctanesulfonate and Other Fluorochemicals in the Serum of American Red Cross Adult Blood Donors

International Union of Basic and Clinical Pharmacology. XC. multisite pharmacology: recommendations for the nomenclature of receptor allosterism and allosteric ligands

Development and pharmacological evaluation of a new chemical series of potent pan-ERR agonists, identification of SLU-PP-915

Randomized, Double-Blind, Placebo-Controlled, Phase II Trial of Sorafenib and Erlotinib or Erlotinib Alone in Previously Treated Advanced Non–Small-Cell Lung Cancer

TMEM16A/ANO1 Channels Contribute to the Myogenic Response in Cerebral Arteries

Improvements in Survival and Clinical Benefit With Gemcitabine as First-Line Therapy for Patients With Advanced Pancreas Cancer: A Randomized Trial

Safety and Activity of Varlilumab, a Novel and First-in-Class Agonist Anti-CD27 Antibody, in Patients With Advanced Solid Tumors

A Randomized, Double‐Blinded, Phase II Trial of Carboplatin and Pemetrexed with or without Apatorsen (OGX‐427) in Patients with Previously Untreated Stage IV Non‐Squamous‐Non‐Small‐Cell Lung Cancer: The SPRUCE Trial

Phase I/II study of bevacizumab with BKM120, an oral PI3K inhibitor, in patients with refractory solid tumors (phase I) and relapsed/refractory glioblastoma (phase II)

LXR-mediated inhibition of CD4+ T helper cells

Synthetic ERRα/β/γ Agonist Induces an ERRα-Dependent Acute Aerobic Exercise Response and Enhances Exercise Capacity

Forebrain-selective AMPA-receptor antagonism guided by TARP γ-8 as an antiepileptic mechanism

Origin of a novel regulatory module by duplication and degeneration of an ancient plant transcription factor

Erlotinib plus either pazopanib or placebo in patients with previously treated advanced non–small cell lung cancer: A randomized, placebo‐controlled phase 2 trial with correlated serum proteomic signatures

Randomized phase 2 trial of pemetrexed, pemetrexed/bevacizumab, and pemetrexed/carboplatin/bevacizumab in patients with stage IIIB/IV non–small cell lung cancer and an Eastern Cooperative Oncology Group performance status of 2

Suchergebnisse filtern